Second-line chemotherapy of epithelial ovarian cancer.
Despite the high objective response rate of advanced epithelial ovarian cancer to front-line chemotherapy, the majority of women with this condition ultimately progress or recur after achieving an initial response and are potential candidates for a second-line treatment approach. A number of antineoplastic agents have demonstrated sufficient biological activity to be considered a rational treatment strategy in this clinical setting. In selecting an 'optimal' management approach for a particular patient the oncologist must consider a number of issues, including the toxicity of the available drugs, the side effects previously experienced by the individual, convenience, cost and patient choice.
Markmon
Maurie
M
Department of Hematology/Medical Oncology, The Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA. markmam@ccf.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D018394:CA-125 Antigen; D009944:Organoplatinum Compounds